Compare Stocks: CHRS, SGMT, CADL, and OLMA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$8.25 +5.9%	$10.93	$4.35 ▼ $14.00	N/A	N/A	N/A	928,459 shs
CHRS Coherus Oncology	$1.07 +5.9%	$1.22	$0.94 ▼ $2.62	N/A	N/A	N/A	604,100 shs
OLMA Olema Pharmaceuticals	$7.04 +6.3%	$9.06	$6.24 ▼ $36.26	$579.24M	2	N/A	2.19 million shs
SGMT Sagimet Biosciences	$10.42 +9.0%	$9.94	$4.50 ▼ $11.45	N/A	N/A	N/A	1.11 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+5.91%	-4.51%	-25.14%	-12.23%	+52.78%
CHRS Coherus Oncology	+5.94%	+7.00%	-5.31%	-24.11%	-33.13%
OLMA Olema Pharmaceuticals	+6.34%	-2.90%	-19.54%	-37.09%	-19.91%
SGMT Sagimet Biosciences	+9.00%	+6.98%	+12.77%	+48.01%	+21.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$8.25 +5.9%	$10.93	$4.35 ▼ $14.00	N/A	N/A	N/A	928,459 shs
CHRS Coherus Oncology	$1.07 +5.9%	$1.22	$0.94 ▼ $2.62	N/A	N/A	N/A	604,100 shs
OLMA Olema Pharmaceuticals	$7.04 +6.3%	$9.06	$6.24 ▼ $36.26	$579.24M	2	N/A	2.19 million shs
SGMT Sagimet Biosciences	$10.42 +9.0%	$9.94	$4.50 ▼ $11.45	N/A	N/A	N/A	1.11 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+5.91%	-4.51%	-25.14%	-12.23%	+52.78%
CHRS Coherus Oncology	+5.94%	+7.00%	-5.31%	-24.11%	-33.13%
OLMA Olema Pharmaceuticals	+6.34%	-2.90%	-19.54%	-37.09%	-19.91%
SGMT Sagimet Biosciences	+9.00%	+6.98%	+12.77%	+48.01%	+21.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.64	Moderate Buy	$21.43	159.74% Upside
CHRS Coherus Oncology	2.33	Hold	$11.00	928.04% Upside
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$40.60	476.70% Upside
SGMT Sagimet Biosciences	2.58	Moderate Buy	$26.63	155.61% Upside

Current Analyst Ratings Breakdown

Latest CHRS, SGMT, CADL, and OLMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/26/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/22/2026	CADL Candel Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$25.00
10/22/2026	CADL Candel Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$25.00
10/15/2026	CADL Candel Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SGMT Sagimet Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	CADL Candel Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/9/2026	CHRS Coherus Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/5/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$29.00
10/2/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/2/2026	SGMT Sagimet Biosciences	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$25.00 ➝ $26.00
10/1/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight

(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	N/A	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)
CHRS Coherus Oncology	N/A	-$1.03	N/A	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
OLMA Olema Pharmaceuticals	N/A	-$2.12	N/A	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
SGMT Sagimet Biosciences	N/A	-$1.28	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)

Latest CHRS, SGMT, CADL, and OLMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	CADL Candel Therapeutics	-$0.3468	N/A	N/A	N/A	N/A	N/A
11/12/2026	Q3 2026	SGMT Sagimet Biosciences	-$0.25	N/A	N/A	N/A	$0.17 million	N/A
11/9/2026	Q3 2026	CHRS Coherus Oncology	-$0.21	N/A	N/A	N/A	$15.98 million	N/A
11/9/2026	Q3 2026	OLMA Olema Pharmaceuticals	-$0.60	N/A	N/A	N/A	$1.25 million	N/A
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/5/2026	Q2 2026	CHRS Coherus Oncology	-$0.25	-$0.19	+$0.06	-$0.13	$14.41 million	$14.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
CHRS Coherus Oncology	72.82%
OLMA Olema Pharmaceuticals	91.78%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
CHRS Coherus Oncology	7.22%
OLMA Olema Pharmaceuticals	12.56%
SGMT Sagimet Biosciences	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	55	N/A	65.58 million	Optionable
CHRS Coherus Oncology	144	N/A	143.35 million	Optionable
OLMA Olema Pharmaceuticals	150	87.50 million	76.51 million	Optionable
SGMT Sagimet Biosciences	16	N/A	55.01 million	Optionable

CHRS, SGMT, CADL, and OLMA Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT) and Revolution Medicines (RVMD)

October 24, 2026 | theglobeandmail.com

Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet

October 23, 2026 | zacks.com

Sagimet Biosciences Begins Pivotal Phase 3 Study Of Denifanstat In Acne Patients

October 22, 2026 | rttnews.com

Sagimet Biosciences Doses First Patient in US Phase 3 Trial of Denifanstat to Treat Acne

October 22, 2026 | finance.yahoo.com

Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne

October 22, 2026 | globenewswire.com

Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet

October 21, 2026 | seekingalpha.com

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) & Sagimet Biosciences (NASDAQ:SGMT) Financial Contrast

October 21, 2026 | americanbankingnews.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Stock Has Average Target Price of $26.63 According to Analysts

October 20, 2026 | americanbankingnews.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Stock Has Consensus Target Price of $26.63

October 20, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Shares Up 7.5% - Here's Why

October 15, 2026 | marketbeat.com

After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

October 15, 2026 | zacks.com

SGMT - Sagimet Biosciences Inc.

October 14, 2026 | seekingalpha.com

Sagimet Biosciences (NASDAQ:SGMT) Shares Down 6.3% - What's Next?

October 13, 2026 | marketbeat.com

Sagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China Trial

October 9, 2026 | finance.yahoo.com

Sagimet Reports Sustained Acne Improvements With Denifanstat Through 52 Weeks

October 9, 2026 | rttnews.com

Sagimet to present 52-week denifanstat acne trial data at Las Vegas conference

October 9, 2026 | streetinsider.com

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the ...

October 9, 2026 | finance.yahoo.com

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

October 9, 2026 | globenewswire.com

HC Wainwright Has Positive Outlook for SGMT FY2026 Earnings

October 7, 2026 | marketbeat.com

What is HC Wainwright's Estimate for SGMT FY2029 Earnings?

October 6, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Stock Falls 6% - Time to Sell?

October 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, SGMT, CADL, and OLMA Company Descriptions

Candel Therapeutics NASDAQ:CADL

$8.25 +0.46 (+5.91%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$8.25 0.00 (0.00%)

As of 10/27/2026 07:48 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Coherus Oncology NASDAQ:CHRS

$1.07 +0.06 (+5.94%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$1.06 -0.02 (-1.40%)

As of 10/27/2026 07:54 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Olema Pharmaceuticals NASDAQ:OLMA

$7.04 +0.42 (+6.34%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$7.06 +0.02 (+0.28%)

As of 10/27/2026 07:30 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Sagimet Biosciences NASDAQ:SGMT

$10.42 +0.86 (+9.00%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$9.93 -0.49 (-4.75%)

As of 10/27/2026 07:30 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHRS, SGMT, CADL, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHRS, SGMT, CADL, and OLMA Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHRS, SGMT, CADL, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, SGMT, CADL, and OLMA Company Descriptions

Candel Therapeutics NASDAQ:CADL

Coherus Oncology NASDAQ:CHRS

Olema Pharmaceuticals NASDAQ:OLMA

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CHRS, SGMT, CADL, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CHRS, SGMT, CADL, and OLMA Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CHRS, SGMT, CADL, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, SGMT, CADL, and OLMA Company Descriptions

Candel Therapeutics NASDAQ:CADL

Coherus Oncology NASDAQ:CHRS

Olema Pharmaceuticals NASDAQ:OLMA

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools